Key facts
- This page summarizes Barbara Klencke's Form 4 filing for ALX ONCOLOGY HOLDINGS INC (ALXO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Apr 2026, 16:15.
Barbara Klencke - 16 Apr 2026 Form 4 Insider Report for ALX ONCOLOGY HOLDINGS INC (ALXO)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- ALXO
- Reported as of
- 16 Apr 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Apr 2026, 16:15:02 UTC
- Prior SEC filing
- 05 Mar 2026
- Next SEC filing
- 22 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shelly Wong, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Barbara Klencke filed Form 4 for ALX ONCOLOGY HOLDINGS INC (ALXO) on 17 Apr 2026.
Change
- Previous filing in this sequence was filed on 05 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001647647
Primary reporting owner
Klencke Barbara
- Relationship
- Chief Medical Officer
- Address
- C/O ALX ONCOLOGY HOLDINGS INC., 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
- Signature
- /s/ Shelly Wong, by power of attorney
- Signature date
- 17 Apr 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALXO
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- Shares
- +100,000
- Change %
- Price
- $0.000000*
- Shares after
- 100,000
- Date
- 16 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $1.68
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
One-fourth of the shares subject to the option vest on February 25, 2027 and 1/48th vest monthly thereafter.